| Protein Name | Transient Receptor Potential Cation Channel Subfamily M Member 7 |
|---|
| Gene | [TRPM7](/genes/trpm7) |
|---|
| UniProt ID | [Q9BX63](https://www.uniprot.org/uniprot/Q9BX63) |
|---|
| PDB Structure | 5M5X, 5L5H, 6O75 |
|---|
| Molecular Weight | 2135 aa (~230 kDa) |
|---|
| Subcellular Localization | Plasma Membrane, Cytoplasm |
|---|
| Protein Family | TRPM (Melastatin) ion channel family |
|---|
| Aliases | CHAK1, LTRPC7, Mg^2+ channel |
|---|
Trpm7 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
TRPM7 (Transient Receptor Potential Cation Channel Subfamily M Member 7) is a unique bifunctional protein that combines an ion channel domain with a serine/threonine kinase domain, making it one of the most structurally distinctive members of the TRP (Transient Receptor Potential) channel superfamily[^1]. This protein is essential for magnesium homeostasis, cellular proliferation, and neuronal development. Dysregulation of TRPM7 has been implicated in several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and various neurodevelopmental disorders[^2].
¶ Dual-Domain Architecture
TRPM7 possesses a unique architecture combining two functional domains:
¶ Channel Domain
- N-terminal Region (1-600 aa): Contains multiple regulatory domains including the MHR (MHR1-3) domains involved in protein interactions and channel regulation[^3]
- Transmembrane Segments (600-900 aa): Six transmembrane helices (S1-S6) form the ion conduction pathway. S1-S4 constitute the voltage-sensor-like domain, while S5-S6 form the pore region
- Ion Selectivity Filter: The pore helix and re-entrant loop determine cation permeability, with preference for Mg2+ and Zn2+ over other cations
- C-terminal Linker: Connects the channel domain to the kinase domain
¶ Kinase Domain
- Alpha-kinase Domain (1200-1800 aa): A serine/threonine-specific protein kinase with unique structure belonging to the alpha-kinase family[^4]
- ATP-binding Site: Located in a deep cleft within the kinase domain
- Autophosphorylation Sites: Multiple serine/threonine residues undergo autophosphorylation, regulating both kinase and channel activity
- C-terminal Region (1800-2135 aa): Contains regulatory elements and the TRP domain
- Phosphorylation: The kinase domain undergoes extensive autophosphorylation. Phosphorylation by other kinases (e.g., Src, AMPK) modulates channel activity[^5]
- Palmitoylation: Affects membrane localization and trafficking
- Glycosylation: N-linked glycosylation in the extracellular loop influences channel biogenesis
TRPM7 functions as a divalent cation channel with unique properties:
Ion Permeability:
- Primary: Mg2+ and Zn2+ (high selectivity)
- Secondary: Ca2+, Na+, K+ (lower permeability)
- Conduction is voltage-dependent and rectification is weak
Physiological Roles:
- Cellular magnesium homeostasis - critical for maintaining intracellular Mg2+ levels
- Zinc signaling in neurons - modulates synaptic transmission
- Calcium homeostasis - contributes to Ca2+ signaling pathways
- Cell volume regulation
Regulation:
- Intracellular Mg2+: Acts as a potent inhibitor at physiological concentrations
- pH: Extracellular and intracellular pH modulate channel gating
- PIP2: Phosphatidylinositol 4,5-bisphosphate is required for channel activity
- Oxidative Stress: Reactive oxygen species (ROS) activate TRPM7
- ATP: Intracellular ATP modulates channel activity
The intrinsic alpha-kinase domain has multiple functions:
- Autophosphorylation: The kinase phosphorylates itself on multiple serine/threonine residues, which is required for full channel activity
- Substrate Phosphorylation: Phosphorylates various substrates including:
- Myosin IIA - regulates cytoskeletal dynamics
- Annexin A1 - involved in membrane trafficking
- TRPM7 itself - modulates channel gating
- Channel Regulation: Kinase activity directly modulates channel open probability and conductance
-
Magnesium Homeostasis: TRPM7 is the primary pathway for Mg2+ uptake in most cell types. Mg2+ is essential for:
- ATP binding and utilization
- DNA/RNA polymerase function
- Protein synthesis
- Neuronal excitability
-
Cell Proliferation: Required for cell cycle progression, particularly G1/S transition
-
Neuronal Development:
- Axon guidance and outgrowth
- Dendritic spine formation
- Synapse development
-
Immune Function: T cell development and function depends on TRPM7-mediated Mg2+ influx
-
Cardiovascular Function: Vascular smooth muscle cell proliferation and contractility
TRPM7 contributes to motor neuron degeneration through multiple mechanisms[^6]:
Mg2+ Dyshomeostasis:
- Altered magnesium homeostasis leads to impaired ATP production
- Reduced Mg2+ affects ribosomal function and protein synthesis
- Energy deficit sensitizes neurons to other insults
Excitotoxicity:
- Increased TRPM7 channel activity under pathological conditions
- Enhanced Ca2+ influx triggers excitotoxic pathways
- Activation of calcium-dependent proteases (calpains)
Oxidative Stress Response:
- ROS activate TRPM7 channels in motor neurons
- Creates a positive feedback loop of oxidative damage
- Mitochondrial dysfunction exacerbates the effect
Therapeutic Implications:
- TRPM7 channel blockers may reduce excitotoxicity
- Magnesium supplementation could compensate for dysregulation
TRPM7 is implicated in dopaminergic neuron loss in PD[^7]:
Mechanisms:
- Oxidative stress in substantia nigra pars compacta activates TRPM7
- Zinc dysregulation contributes to neuronal death
- Magnesium deficiency in PD patients may reflect TRPM7 dysfunction
Neuroprotection:
- TRPM7 inhibition protects dopaminergic neurons
- Channel blockers reduce 6-OHDA-induced toxicity
- Modulation represents a potential therapeutic strategy
TRPM7 variants cause developmental defects:
- Impaired Neurite Outgrowth: Essential for axonal development
- Altered Brain Development: Cortical malformations in knockout models
- Intellectual Disability: TRPM7 mutations associated with neurodevelopmental delay
- Congenital Disorders: Wholegene deletions cause prenatal lethality
TRPM7 dysfunction causes:
- Guamanian ALS/PDC: TRPM7 polymorphisms associated with the cluster of ALS-PDC in Guam
- Ankyrin Repeat Domain 7 Deficiency: TRPM7 variants cause early-onset neurodegeneration
- Channelopathies: Gain-of-function and loss-of-function mutations
Pharmaceutical inhibition of TRPM7 channels:
- Waixenicin A: A natural compound from Wai extracts that selectively inhibits TRPM7
- Carvacrol: Non-selective TRP agonist with inhibitory effects on TRPM7
- Mg2+: High extracellular Mg2+ blocks the channel
Targeting the kinase domain:
- Small molecule inhibitors: Under development for neuroprotection
- Phosphorylation site modulators: Target autophosphorylation
- Channel Blocker + Neuroprotective Agents: Combined strategies
- Gene Therapy: Targeting TRPM7 expression or function
| Challenge |
Current Approach |
| Specificity |
Developing selective blockers |
| Delivery |
CNS penetration is limited |
| Safety |
Mg2+ homeostasis must be maintained |
The seminal discovery by Nadler et al. (2001) identified TRPM7 as a magnesium channel essential for cellular Mg2+ homeostasis[^8]. This was the first identification of a molecular pathway for magnesium entry in mammalian cells.
TRPM7 is unique in combining ion channel and kinase functions. Research has shown that these activities are functionally coupled - kinase activity modulates channel gating, and channel activity can regulate kinase function[^9].
Hermosura et al. (2008) demonstrated that TRPM7 mediates oxidative stress-induced neuronal death, establishing a direct link between TRPM7 dysfunction and neurodegenerative disease[^10].
Trpm7 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Trpm7 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Nadler et al., TRPM7 is a magnesium channel (2001)
- Hermosura et al., TRPM7 in neurodegeneration (2008)
- Fujii et al., TRPM7 structure and function (2020)
- Yamaguchi et al., Alpha-kinase domain structure (2001)
- Runnels et al., TRPM7 regulation by phosphorylation (2002)
- Song et al., TRPM7 in ALS pathogenesis (2020)
- Wu et al., TRPM7 in Parkinson's disease (2013)
- Nadler et al., Molecular identification of TRPM7 (2001)
- Matsushita et al., Channel-kinase coupling (2005)
- Hermosura et al., TRPM7-mediated oxidative stress (2008)